Frontier Pharma Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation

1
Frontier Pharma Parkinsons Disease - Identifying
and Commercializing First-in-Class Innovation
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• Parkinsons Disease (PD) is the second most common
  neurodegenerative disease after Alzheimers
  disease, affecting around 7.4 million people
  worldwide. It is caused by the progressive loss
  of dopamine-producing neurons in the substantia
  nigra within the basal ganglia. The main motor
  symptoms are tremors, bradykinesia and rigidity,
  although symptoms vary between individuals. As
  the disease progresses to more advanced stages,
  increasing symptoms and complications develop,
  which can cause severe disability in patients.
• The current market offers a number of anti-PD
  treatment options which provide symptomatic
  relief. Levodopa is currently the gold standard
  therapy, with other drug classes including
  dopamine agonists and Monoamine Oxidase B (MAO-B)
  inhibitors also used to treat early and advanced
  cases. With no current treatment showing
  effectiveness in delaying the course of the
  disease, PD remains incurable. The high unmet
  need for a disease-modifying therapy is reflected
  in the pipeline, where a high proportion of
  early-stage first-in-class programs target the
  potential pathogenic mechanisms underlying
  neurodegeneration.
• Read More At http//www.researchbeam.com/frontier
  -pharma-parkinsons-disease-identifying-and-commerc
  ializing-first-in-class-innovation-market

3


Table of Content
1 Table of Contents 2 1.1 List of Tables 3 1.2
List of Figures 3 2 Executive Summary 4 2.1 High
Unmet Needs Remain in Parkinsons Disease Market
4 2.2 Diverse and Innovative Pipeline to Shift
Focus to Disease Modification 4 3 The Case for
Innovation 5 3.1 Growing Opportunities for
Biologic Products 6 3.2 Diversification of
Molecular Targets 6 4 Clinical and Commercial
Landscape 9 4.1 Disease Overview 9 4.2
Epidemiology 9 5 Assessment of Pipeline Product
Innovation 35 5.1 Parkinsons Disease Pipeline by
Molecule Type, Phase and Therapeutic Target
35 5.2 Comparative Distribution of Programs
between Parkinsons Disease Market and Pipeline by
Therapeutic Target Family 40
4


Table of Content
6 Signaling Pathways, Genetics and Innovation
Alignment 45 6.1 The Complexity of Signaling
Networks in the Central Nervous System 45 6.2
Signaling Pathways and First-in-Class Molecular
Target Integration 46 7 First-in-Class Target
Evaluation 49 7.1 Pipeline Programs Targeting
?-synuclein 49 7.2 Pipeline Programs Targeting
DJ-1 52 8 Deals and Strategic Consolidations
72 8.1 Industry-Wide First-in-Class Deals 72 8.2
Licensing Deals 73 9 Appendix 82 9.1
Abbreviations 82 9.2 Bibliography 84 Enquire
At http//www.researchbeam.com/frontier-pharma-p
arkinsons-disease-identifying-and-commercializing-
first-in-class-innovation-market/enquire-about-rep
ort
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/frontier-pharma-parkin
sons-disease-identifying-and-commercializing-first
-in-class-innovation-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com